. 2015 Apr 20;2(2):133–146. doi: 10.2217/hep.15.7

Table 2. . Liver directed radiation outcomes for hepatocellular carcinoma with tumor vein thrombosis.

Author	Institution	Study design	Pts	Tumor size (range)	Prior non-RT trtmt (%)	Trtmt	Dose (range) in Gy	Fx	ORR^† (%)	1-year OS (%)	MS (mo)	Grade ≥3 toxicity (%)	Ref.
Bujold et al.	Princess Margaret Hospital	Prospective	56	1.8–23.1 cm	52^‡	SBRT	36 (24–54)	6	NR	44	10.6	36^†	[44]

Xi et al.	Guangzhou, China	Retrospective	41	NR	100	SBRT	36 (30–48)	6	75.6	50	13	2.40	[86]

Sugahara et al.	University of Tsukuba, Japan	Retrospective	35	2.5–13 cm	77.8	Proton	72.6 (55–77) GyE	2.2–5.5 GyE/fx	63 Primary	48 at 2 years	22	8.60	[87]
									55.6 TVT				[87]

Choi et al.	Catholic University, Korea	Retrospective	9	3.9–47.7 ml	83.9^§	SBRT	36 (30–39)	3	44.4	43.20	8	16^†	[88]

Yoon et al.	Asan Medical Center, Korea	Retrospective	412	2–21 cm	NR	3D-CRT + TACE	40 (21–60)	2–5 Gy/fx	28 Primary	43	10.6	10	[89]
									39.6 TVT				[89]

Rim et al.	Korea University Medical Center	Retrospective	45	1.5–17.3 cm	93.3	3D-CRT	61.2 (38–65)	1.8–2.5 Gy/fx	62.3 TVT	52	13.9	2	[90]

Chuma et al.	Hokkaido University, Japan	Retrospective	20	6–14.5 cm	55	3D-CRT + intra-arterial-5FU and SubQ-IFN	30–48	6–20	60 TVT	NS	10.6	15	[91]

Huang et al.	Kaohsiung Medical Center, Taiwan	Retrospective	326	≥10cm in 39%	NR	3D-CRT	60	20–30	17.1 TVT	17	3.8	0	[92]

Kang et al.	Navy General Hospital, Beijing, China	Retrospective	101	NR	NR	SBRT → TACE	40.2 (21–60)	6	88.2	58.8	17	32.4	[93]

						TACE → SBRT			89.2	54.1	15	40.5	[93]

						SBRT			83.3	500	12	30.0	[93]

Lin	Taipei, Taiwan	Prospective	9 7	6.5 cm (median) 13.8 cm (median)	NR	Fractionated SBRT 3D-CRT	45 45	15 25	75 84	NR	6 6.7	NR	[94]

^†Grade 3+ toxicity reported for all patients with and without TVT.

^‡Did not specify prior trtmt for patients w/versus w/o TVT.

^§Includes additional pts without TVT.

3D-CRT: 3D conformal radiation therapy; CP Class: Child–Pugh class; Fx: Fractions; LC: Local control; KIRMS: Korea institute of radiological and medical sciences; NR: Not reported; MS: Median survival; ORR: Overall response rate (CR+PR), specified response for primary tumor and TVT when available; OS: Overall survival; Pts: Patients; SBRT: Stereotactic body radiotherapy; SubQ-IFN: Subcutaneous interferon; TACE: Trans-arterial chemoembolization; Trtmt: Treatment; TVT: Tumor vein thrombosis.